Guanglin Luo, Newtown, PA (US); Carolyn Diane Dzierba, Middletown, CT (US); and John E. Macor, Washington Crossing, PA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Filed on Mar. 5, 2021, as Appl. No. 17/192,985.
Application 17/192,985 is a continuation of application No. 16/913,064, filed on Jun. 26, 2020, granted, now 10,981,910.
Application 16/913,064 is a continuation of application No. 16/443,929, filed on Jun. 18, 2019, granted, now 10,723,734, issued on Jul. 28, 2020.
Application 16/443,929 is a continuation of application No. 16/168,533, filed on Oct. 23, 2018, granted, now 10,351,563, issued on Jul. 16, 2019.
Application 16/168,533 is a continuation of application No. 15/865,848, filed on Jan. 9, 2018, granted, now 10,155,760, issued on Dec. 18, 2018.
Application 15/865,848 is a continuation of application No. 15/300,618, granted, now 9,902,722, issued on Feb. 27, 2018, previously published as PCT/US2015/023805, filed on Apr. 1, 2015.
Claims priority of provisional application 62/061,591, filed on Oct. 8, 2014.
Claims priority of provisional application 61/973,942, filed on Apr. 2, 2014.
Prior Publication US 2021/0277001 A1, Sep. 9, 2021
1. A method of treating diabetic neuropathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine, or a pharmaceutically acceptable salt thereof, and an anti-diabetic agent.